News | October 06, 2025
Lilly to invest $1 billion+ in new contract manufacturing in India
Investment to expand manufacturing and global medicine supply capacity
Investment to expand manufacturing and global medicine supply capacity
Commercial production is expected to begin soon
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
The newly commissioned facility strengthens the ’company’s capabilities in the development and manufacturing of generic and complex sterile injectable products
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
